National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Drug Events (ADE) (1)
- Adverse Events (1)
- Antibiotics (2)
- Antimicrobial Stewardship (2)
- Behavioral Health (1)
- Blood Thinners (1)
- Cardiovascular Conditions (1)
- (-) COVID-19 (9)
- Evidence-Based Practice (1)
- Healthcare Delivery (1)
- Health Information Technology (HIT) (1)
- Medicare (1)
- (-) Medication (9)
- Medication: Safety (1)
- Opioids (2)
- Patient Safety (1)
- Practice Patterns (2)
- Public Health (1)
- Respiratory Conditions (2)
- Substance Abuse (1)
- Telehealth (1)
- Treatments (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 9 of 9 Research Studies DisplayedKravchenko OV, Boyce RD, Gomez-Lumbreras A
Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the national COVID cohort collaborative (N3C).
This study examined whether there is an association between thromboembolotic events (TEEs) and concomitant use of dexamethasone with either apixaban or rivaroxaban (both direct oral anticoagulants or DOACs) during treatment for COVID-19. The authors used data from the National COVID Cohort Collaborative (N3C) to conduct a nested case-control study. Eligible participants were adults over 18 years who were exposed to a DOAC for 10 or more consecutive days and exposure to dexamethasone at least 5 or more consecutive days. The study did not find a discernible association of TEE in patients concomitantly exposed to dexamethasone and a DOAC.
AHRQ-funded; HS025984.
Citation: Kravchenko OV, Boyce RD, Gomez-Lumbreras A .
Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the national COVID cohort collaborative (N3C).
BMJ Open 2022 Dec 29; 12(12):e066846. doi: 10.1136/bmjopen-2022-066846..
Keywords: COVID-19, Blood Thinners, Medication, Adverse Drug Events (ADE), Adverse Events, Cardiovascular Conditions, Medication: Safety, Patient Safety
Redwood R, Schulz LT, Pop-Vicas A
A perfect storm: COVID-19 and antimicrobial resistance.
The purpose of this article was to discuss key factors that contributed to the impact of the COVID-19 pandemic on antimicrobial resistance (AMR) with an emphasis on lessons learned and next steps. The authors report that the pandemic strained healthcare systems worldwide and disrupted standard infection control and antimicrobial stewardship practices, which are essential to limit the spread of multidrug-resistant organisms and decrease selective pressure related to inappropriate or unnecessary antimicrobial therapy. Disruptions to these practices are compounded by the disproportionately long hospital and intensive care unit stays observed in critically ill COVID-19 patients, leading to secondary bacterial infections that are notoriously difficult to treat and increase the use of broad-spectrum antibiotics, which can drive resistance. The article further states that the pandemic has led to shortages in personal protective equipment, increased workload, and staffing issues, all of which have disrupted routine antimicrobial stewardship activities. The article concludes that COVID-19 pandemic has highlighted the need to develop new therapeutic interventions for infectious diseases that do not rely solely on antibiotics, and stresses the importance of incorporating the lessons learned from the COVID-19 pandemic into future efforts to combat AMR.
AHRQ-funded; HS028669.
Citation: Redwood R, Schulz LT, Pop-Vicas A .
A perfect storm: COVID-19 and antimicrobial resistance.
EMJ, Microbiol Infect Dis 2022 Sep; 2022. doi: 10.33590/emjmicrobiolinfectdis/22-00082..
Keywords: COVID-19, Antimicrobial Stewardship, Antibiotics, Medication
Beetham T, Fiellin DA, Busch SH
Physician response to COVID-19-driven telehealth flexibility for opioid use disorder.
This study surveyed physicians who provide opioid use disorder (OUD) treatment on their preferences and practices regarding telehealth that have evolved during the COVID-19 pandemic. A total of 1141 physicians who were publicly listed buprenorphine-prescribing physicians were surveyed. Most respondents found telehealth to be effective, with 54% who found it more effective than expected. Overall, 85% were in favor of temporary telehealth flexibility being permanently extended, and 77% would be likely to use telehealth after the COVID-19 pandemic is over.
AHRQ-funded; HS017589.
Citation: Beetham T, Fiellin DA, Busch SH .
Physician response to COVID-19-driven telehealth flexibility for opioid use disorder.
Am J Manag Care 2022 Sep;28(9):456-63. doi: 10.37765/ajmc.2022.89221..
Keywords: COVID-19, Telehealth, Health Information Technology (HIT), Opioids, Substance Abuse, Behavioral Health, Medication
Keller SC, Caballero TM, Tamma PD
AHRQ Author: Miller MA
Assessment of changes in visits and antibiotic prescribing during the Agency for Healthcare Research and Quality Safety Program for Improving Antibiotic Use and the COVID-19 pandemic.
This cohort study evaluated the effectiveness of the AHRQ Safety Program for Improving Antibiotic Use aimed to improve antibiotic prescribing in ambulatory practices by engaging clinicians and staff to incorporate antibiotic stewardship into practice culture, communication, and decision-making. The study ran from December 2019 through November 2020. A total of 389 ambulatory care practices with over 6.5 million visits to 5483 clinicians were compared from the baseline to completion of the program. Participants included 82 primary care practices, 103 urgent care practices, 34 federally supported practices, 21 pediatric-only practices, 39 pediatric urgent care practices, 21 pediatric-only practices, and 14 other practice types. Of the 389 practices who completed the program, 75% submitted completed data. Visits per practice per month decreased from a mean of 1624 at baseline to a nadir of 906 early in the COVID-19 pandemic (April 2020) and were 1797 at the end of the program. Total antibiotic prescribing decreased from 18.2% of visits at baseline to 9.5% at completion of the program. Acute respiratory infection (ARI) visits per practice per month decreased from a baseline of 321 to a nadir of 76 early in the pandemic (May 2020) and gradually increased through completion of the program (n = 239). Antibiotic prescribing for ARIs decreased from 39.2% at baseline to 24.7% at completion of the program.
AHRQ-authored; AHRQ-funded; 233201500020I.
Citation: Keller SC, Caballero TM, Tamma PD .
Assessment of changes in visits and antibiotic prescribing during the Agency for Healthcare Research and Quality Safety Program for Improving Antibiotic Use and the COVID-19 pandemic.
JAMA Netw Open 2022 Jul;5(7):e2220512. doi: 10.1001/jamanetworkopen.2022.20512..
Keywords: Antimicrobial Stewardship, Antibiotics, Medication, COVID-19, Public Health, Respiratory Conditions
Behr CL, Joynt Maddox KE, Meara E
Anti-SARS-CoV-2 monoclonal antibody distribution to high-risk Medicare beneficiaries, 2020-2021.
The authors assessed how the limited supply of monoclonal antibodies (mAbs) therapy was allocated to patients at highest risk of severe disease. They found that, among non-hospitalized Medicare beneficiaries with a COVID-19 diagnosis between November 2020 and August 2021, only 7.2% received mAb therapy. In many cases, patients at the highest risk of severe disease were the least likely to receive mAb therapy, with extreme variation geographically. Their analysis did not account for patient vaccination status or observed disease severity, which could influence clinicians’ decisions.
AHRQ-funded; HS024075.
Citation: Behr CL, Joynt Maddox KE, Meara E .
Anti-SARS-CoV-2 monoclonal antibody distribution to high-risk Medicare beneficiaries, 2020-2021.
JAMA 2022 Mar 8;327(10):980-83. doi: 10.1001/jama.2022.1243..
Keywords: COVID-19, Medicare, Medication
Douin DJ, Krause M, Williams C
Corticosteroid administration and impaired glycemic control in mechanically ventilated COVID-19 patients.
This study’s objective was to determine the association between corticosteroid administration and impaired glycemic control among COVID-19 patients requiring mechanical ventilation and/or veno-venous extracorporeal membrane oxygenation. This multicenter retrospective cohort study was conducted between March 9 and May 17, 2020 at 12 US hospitals. The primary outcome measured was days spent with at least 1 episode of blood glucose either >180 mg/dL or <80 mg/dL within the first 28 days of admission. The authors included 292 mechanically ventilated patients. Sixty-six patients (22.6%) died within 28 days of ICU admission. Seventy-one patients (24.3%) received a cumulative dose of at least an equivalent of 320 mg methylprednisolone. After adjustment for gender, history of diabetes mellitus, chronic liver disease, sequential organ failure assessment score on intensive care unit day 1, and length of stay, administration of ≥320 mg methylprednisolone equivalent was associated with 4 additional days spent with glucose either <80 mg/dL or >180 mg/dL.
AHRQ-funded; HS027795.
Citation: Douin DJ, Krause M, Williams C .
Corticosteroid administration and impaired glycemic control in mechanically ventilated COVID-19 patients.
Semin Cardiothorac Vasc Anesth 2022 Mar;26(1):32-40. doi: 10.1177/10892532211043313..
Keywords: COVID-19, Treatments, Medication
Rikin S, Perez HR, Zhang C
Changes in outpatient opioid prescribing during the COVID-19 pandemic: an interrupted time series analysis.
Changes in health care delivery during the COVID-19 pandemic may have impacted opioid prescribing. This study evaluated the impact of restrictions on in-person care on opioid prescribing in the outpatient setting. The hypothesis was that after restrictions to in-person care were implemented, there would be a reduction in the number of chronic and non-chronic opioid prescriptions.
AHRQ-funded; HS026396.
Citation: Rikin S, Perez HR, Zhang C .
Changes in outpatient opioid prescribing during the COVID-19 pandemic: an interrupted time series analysis.
J Prim Care Community Health 2022 Jan-Dec;13:21501319221076926. doi: 10.1177/21501319221076926..
Keywords: COVID-19, Opioids, Medication, Practice Patterns, Healthcare Delivery
Levin Z, Chang J, Karaca-Mandic P
Characteristics of hydroxychloroquine dispensing in the United States, January to May 2020.
This research letter describes a comparison of hydroxychloroquine (HCQ) prescription trends from January to May 2020. The authors identified HCQ dispensing from the OptumLabs Data Warehouse and identified 66,253 enrollees with 134,417 HCQ fills during the study period. Nearly 13,000 new fillers (67.2%) did not have a diagnostic indication of lupus, rheumatoid arthritis, malaria or Sjogren’s syndrome. Among previous fillers, 15.1% had no indication. The most common diagnosis was RA among indicated users. The rate of HCQ fills per 1,000 enrollees increased substantially in mid-March among both new and previous HCQ fillers. For prior fillers, rates increased due to an anticipated shortage of the drug due to people using it for COVID-19 prevention.
AHRQ-funded; HS025164.
Citation: Levin Z, Chang J, Karaca-Mandic P .
Characteristics of hydroxychloroquine dispensing in the United States, January to May 2020.
J Gen Intern Med 2022 Jan;37(1):176-78. doi: 10.1007/s11606-021-07175-9..
Keywords: COVID-19, Medication, Practice Patterns
Hernandez AV, Roman YM, Pasupuleti V
Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review.
Investigators summarized evidence about the benefits and harms of hydroxychloroquine or chloroquine for the treatment or prophylaxis of coronavirus disease 2019 (COVID-19). They found that evidence on the benefits and harms of using hydroxychloroquine or chloroquine to treat COVID-19 was very weak and conflicting.
AHRQ-funded; 290201500012I.
Citation: Hernandez AV, Roman YM, Pasupuleti V .
Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review.
Ann Intern Med 2020 Aug 18;173(4):287-96. doi: 10.7326/m20-2496..
Keywords: COVID-19, Respiratory Conditions, Medication, Evidence-Based Practice